Former Boston Scientific Exec Joins Transverse Medical’s Board

Transverse Medical Inc. has appointed professor Ian T. Meredith, M.D., to its Board of Directors. Dr. Meredith has more than 35 years of experience and global leadership in cardiology coupled with successful clinical trials and device commercialization of multiple interventional products.

Dr. Meredith is joining the board as an independent member. He retired from Boston Scientific Corp. in April 2023 after serving six years as executive vice president and global chief medical officer. During his Boston Scientific tenure, Dr. Meredith was the global leader of medical affairs, trial strategy, and clinical science. Notably, he was involved with Boston Scientific’s acquisition of Claret Medical and the Sentinel Cerebral Embolic Protection (CEP) technology. Under his tenure, subsequent post-market approval clinical studies focused on stroke reduction and the clinical merits of CEP during transcatheter aortic valve replacement (TAVR).

“I’m looking forward to Dr. Meredith joining the Board of Directors for his corporate experience and board role, as well as his medical and clinical expertise in support of the success of the next generation POINT-GUARD and the company’s future clinical plans and strategy,” Transverse Medical President/CEO Eric Goslau said. “I’ve admired and followed Dr. Meredith throughout his career, and it gives me great pleasure to welcome him to the board.”

Dr. Meredith’s contributions to the cardiovascular space, his corporate and industry experience, his extensive years as a clinical and interventional cardiologist coupled with his tenure serving as professor and director of Monash-Heart in Melbourne Australia supports Transverse Medical’s present and future business strategy. In addition to Meredith’s independent board director role with Transverse Medical, the medical affairs team solicit his contributions and involvement with the company’s upcoming and future clinical planning.

“I have the highest respect for Dr. Meredith for all that he has contributed to the cardiovascular space. I’m enthusiastic about him joining the company’s board and especially for his expertise and success with clinical trial design and medical device market introduction,” Transverse Medical Chief Medical Officer Dr. Michael Reardon stated. “I’m confident that his successful experience will help bring the POINT-GUARD device through a successful trial and subsequently to market.”

“I’m a great believer in the need for meaningful cerebral embolic protection in the setting of invasive and surgical cardiac procedures. Although embolic stroke is a low frequency event following complex coronary interventions and structural heart procedures, I have witnessed the devastating and debilitating impact of embolic stroke on patient’s lives,” Dr. Meredith remarked. “A stroke rate of zero is the goal. This is why I was and remain particularly supportive of BSC’s move to acquire Claret in 2018. I also believe an unmet need remains and improvement is needed with CEPs. There are many CEPs in development, but I’m most impressed with the POINT-GUARD design and solution for full brain protection given its simplicity and unique device attributes.”

“Joining TMI’s Board of Directors continues my mission to support and contribute to bringing needed medical technologies to all patients around the world,” Dr. Meredith continued. “It still chills me when I recollect that patients would often express to me, as I outlined the potential risks of TAVR, their deeply personal reservations such as ‘I am older, I have had a good life, I am not fearful of dying, I just fear having a stroke.'”

Transverse Medical is an early-stage medical device company developing the POINT-GUARD Cerebral Embolic Protection medical device. The Point-Guard solution for full brain protection during TAVR introduces a simple approach for maximum aortic arch coverage to address the risk of stroke during TAVR. Point-Guard is being developed to protect patients from embolic debris (particles) that are dislodged and released (debris shower) into the cerebral blood flow that could lead to periprocedural stroke as a result of the TAVR procedure.

The next-generation Point-Guard is a breakthrough advancement for complete cerebral embolic protection of the brain and designed with operator ease of use and ability to accommodate variable arch anatomies with low interference and full aortic arch stabilization.

The POINT-GUARD is currently in development and has not been approved for human use by the U.S. Food and Drug Administration or any regulatory authority.